E
Estrella Immunopharma, Inc. (ESLA)
NCM – Real vaqt narxi. Valyuta: USD
1.05
+0.01 (0.96%)
Yopilishda: Mar 27, 2026, 4:00 PM EDT
1.08
+0.03 (2.85%)
Bozordan keyin: Mar 27, 2026, 5:18 PM EDT
Aksiya tahlili uchun eng kuchli vositalarga ega bo'ling
NCM – Real vaqt narxi. Valyuta: USD
1.05
+0.01 (0.96%)
Yopilishda: Mar 27, 2026, 4:00 PM EDT
1.08
+0.03 (2.85%)
Bozordan keyin: Mar 27, 2026, 5:18 PM EDT
Estrella Immunopharma, Inc., klinik bosqichdagi biofarmatsevtika kompaniyasi, Qo'shma Shtatlarda qon saratoni va qattiq o'smalar uchun T-hujayrali terapiyalarni ishlab chiqadi. Kompaniyaning asosiy mahsulot nomzodlari quyidagilardir: EB103, diffuziya katta B-hujayrali limfoma davolash uchun I/II bosqichli klinik sinovda; EB104, diffuziya katta B-hujayrali limfoma va o'tkir limfoblastik leykemiyani davolash uchun preklinik sinovda; va EB201, tizimli qizil yugurukni davolash uchun preklinik sinovda. Kompaniya gematologik o'smalarni davolash uchun CD19 va CD22 ni nishonga olgan T-hujayrali terapiyalarni ishlab chiqish va tijoratlashtirish uchun ARTEMIS, hujayra retseptor platformasini taklif etadi. Kompaniya Imugene'ning CF33-CD19t mahsulot nomzodidan EB103 bilan birgalikda qattiq o'smalarni davolash uchun Eureka va Imugene Limited bilan hamkorlik shartnomasiga ega. Estrella Immunopharma, Inc. 2006 yilda tashkil etilgan va shtab-kvartirasi Kaliforniyaning EmeryVille shahrida joylashgan. Estrella Immunopharma, Inc. Eureka Therapeutics, Inc. kompaniyasining sho'ba korxonasidir.
| Ism | Lavozim |
|---|---|
| Dr. Cheng Liu Ph.D. | CEO, President & Director |
| Mr. Jiandong Xu | Chief Financial Officer |
| Sana | Turi | Hujjat |
|---|---|---|
| 2026-01-22 | S-1/A | ea0269161-03.htm |
| 2026-01-16 | S-1/A | ea0269161-02.htm |
| 2026-01-13 | 8-K | ea027282201-8k_estrellaimmu.htm |
| 2026-01-06 | 8-K | ea0271975-8k_estrella.htm |
| 2025-12-22 | S-1 | ea0269161-01.htm |
| 2025-12-04 | 8-K | ea0268496-8k_estrella.htm |
| 2025-11-12 | 10-Q | ea0262756-10q_estrella.htm |
| 2025-11-06 | 8-K | ea0264099-8k_estrella.htm |
| 2025-09-29 | 8-K | ea0259355-8k_estrella.htm |
| 2025-09-26 | 8-K | ea0259031-8k_estrella.htm |